Catching you up on the week of August 4–10, 2025: the trial milestones, regulatory moves, and business developments shaping psychedelic medicine right now.
Cybin Inc. (CYBN): Cybin to present at Canaccord Genuity 45th Annual Growth Conference
Cybin disclosed via an SEC filing that CEO Doug Drysdale would take part in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025 in Boston. The appearance kept the company in front of institutional investors ahead of its fiscal Q1 2026 results and continued progress on the CYB003 Phase 3 EMBRACE study. It is a routine investor-relations event rather than a clinical catalyst.
Source: sec.gov
GH Research (GHRS): GH Research Q2 2025: strong cash position and 73% six-month remission in GH001 extension
GH Research reported a Q2 2025 net loss of $9.3 million and cash of $308.7 million. The company said its full open-label extension analysis for GH001 (inhaled 5-MeO-DMT) in treatment-resistant depression confirmed a 73% remission rate at six months without mandated psychotherapy and no treatment-related serious adverse events. It reiterated that only one topic remained on the GH001 IND clinical hold and that it planned to start its global pivotal program in 2026.
Source: globenewswire.com
Germany (psilocybin policy) (—): Forbes coverage amplifies Germany's approval of the EU's first psilocybin access program
Forbes published a detailed August 7 account of Germany's newly launched compassionate-use program giving treatment-resistant depression patients supervised access to psilocybin, the first such access route in the EU. The coverage underscored the role of Filament Health's PEX010 and the initial capacity constraints at participating clinics. The high-profile reporting extended sector attention to a policy development seen as a template for broader European access.
Source: forbes.com
That's the recap. Follow the Psychedelic Invest Index for how the sector is trading, and check back next week for the next edition.